Several studies have shown that the combination of Montanide with the peptides of the oncoproteins E6 and E7 stimulates both CD4+ and CD8+ T lymphocytes, favoring a more robust and tumor-directed immune response [106,133]. This evidence concerns the gene CD4 and neoplasm.